MedTrace Logo

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

NCT04118062 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-09-19

No results posted yet for this study

Summary

Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context still constitutes a challenge. When resistance to cancer treatments occurs, physicians not only have to explain to the patient the phenomenon of resistance, often based on complex results (biological results, genomic tests, imaging, etc.), but also need to offer alternative therapies, whilst fostering shared medical decision-making. These different tasks are particularly challenging for clinicians, especially since there are large individual differences at patient level. Indeed, each patient has his or her own unique information needs, capacity for understanding, and level of desire to participate in treatment decisions.

Conditions

Interventions

BEHAVIORAL

Questionnaires

Questionnaires

BEHAVIORAL

Semi-structured individual interviews

Semi-structured individual interviews

OTHER

Focus Group

Focus Group

OTHER

DELPHI Consensus Method

DELPHI Consensus Method

Sponsors & Collaborators

  • Institut Curie

    lead OTHER

Principal Investigators

  • Sylvie DOLBEAULT, PHD · Institut Curie

  • Anne BREDART, PHD · Institut Curie

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2023-05-26
Completion
2024-05-26

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118062 on ClinicalTrials.gov